¡Ya estamos en ! Descubre más
icono de CLOV

Clover Health Investments

4.48 USD
-0.20
4.27%
Al cierre Actualizado 16 oct, 4:00 p.m. EDT
Antes de la apertura del mercado
Después del cierre del mercado
4.50
+0.02
0.45%
1 día
-4.27%
5 días
-6.28%
1 mes
-1.75%
3 meses
1.82%
6 meses
107.41%
En lo que va del año
85.89%
1 año
65.93%
5 años
-43.22%
10 años
-56.08%
 

Acerca de: Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

Empleados: 724

Noticias

Positivo
Neutral
Negativo
Sentimiento 3 meses
Positivo 33.3%
Neutral 61.1%
Negativo 5.6%
Neutral
GlobeNewsWire
hace 8 días
Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
WILMINGTON, Del., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that the Centers for Medicare & Medicaid Services (“CMS”) has awarded its PPO Medicare Advantage (“MA”) plans a rating of 5 Stars and its HMO MA plan a rating of 4.5 Stars for 2027, which will affect payment year 2028.
Clover Health Medicare Advantage PPO Plans Earn 5 Star Rating for 2027
Neutral
GlobeNewsWire
hace 9 días
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
WILMINGTON, Del., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced that it will release its financial results after the market closes on Wednesday, November 4, 2026.
Clover Health to Report Third Quarter 2026 Financial Results on November 4, 2026
Neutral
GlobeNewsWire
hace 16 días
Clover Health's 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
WILMINGTON, Del., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced its 2027 Medicare Advantage (MA) plan offerings, with a continued focus on PPO choice, affordable access to preventive care and meaningful member value.
Clover Health's 2027 Medicare Advantage Plans Emphasize PPO Choice, Preventive Care and Member Value
Neutral
GlobeNewsWire
hace 22 días
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D.
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.
UPDATE – Clover Health Welcomes Former U.S. Senator Robert Torricelli and Dr. Brian J. Miller M.D.
Neutral
GlobeNewsWire
hace 22 días
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D.
WILMINGTON, Del., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) today announced the appointments of former U.S. Senator Robert Torricelli and Dr. Brian J.
Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D.
Positivo
MarketBeat
hace 29 días
Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens
Clover Health Investments NASDAQ: CLOV is positioning its Medicare Advantage business to benefit from industry pricing discipline, member retention and the maturation of member cohorts, Interim Chief Financial Officer Clay Thornton said at Jefferies' Healthcare Services and Technology Conference in Nashville.
Clover Health Sees PPO Edge, Cohort Gains as Medicare Advantage Pricing Tightens
Neutral
GlobeNewsWire
el mes pasado
Clover Health to Participate in Upcoming Investor Conferences
WILMINGTON, Del., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”), today announced its participation in the following investor conferences: Interim Chief Financial Officer, Clay Thornton, will present at the 2026 Jefferies Healthcare Services and Technology Conference on Tuesday, September 15, 2026, at 1:40 p.m.
Clover Health to Participate in Upcoming Investor Conferences
Positivo
Seeking Alpha
el mes pasado
Clover Health Is A 'Buy' Because Of Its AI
Clover Health Investments, Corp. leverages its AI-powered Clover Assistant to drive lower claims costs and improve member profitability. Baseline and bullish DCF valuations yield fair values of $5.02 and $14.10 per share, respectively, versus the current $4.15 price. Key upside drivers include rapid membership growth, AI-enabled cost savings, and a potential $120M Medicare Advantage bonus tied to a 4.5-star CMS rating.
Clover Health Is A 'Buy' Because Of Its AI
Neutral
Seeking Alpha
hace 2 meses
Clover Health Investments: Real Turnaround, But Already Priced In
Clover Health Investments (CLOV) is rated Hold, with operational execution but a cautious outlook due to valuation and litigation risks. CLOV's Medicare Advantage membership grew 48% YoY, revenue and GAAP net income improved, but profitability per member lags FY2024 levels. FY2026 guidance implies negative H2 results; $120M in quality bonus revenue is at risk pending CMS litigation outcome.
Clover Health Investments: Real Turnaround, But Already Priced In
Positivo
Seeking Alpha
hace 2 meses
Clover Health Is Proving Its Profit Model
Clover Health (CLOV) has delivered strong growth, profitability, and improved guidance, supporting my continued Strong Buy rating. CLOV's Medicare Advantage membership grew 48% YoY, with revenue up 56% and gross profit up 54%, driven by cohort maturation and the Clover Assistant platform. Valuation remains attractive at a 78% discount to sector median EV/sales, with upside potential if per-member profitability and SaaS revenue trends persist.
Clover Health Is Proving Its Profit Model
Gráficos de precios implementados con Lightweight Charts™